CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Advisory Services Network LLC

Advisory Services Network LLC lowered its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 43.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,057 shares of the company's stock after selling 7,629 shares during the period. Advisory Services Network LLC's holdings in CRISPR Therapeutics were worth $396,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Geode Capital Management LLC boosted its holdings in CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock valued at $47,383,000 after acquiring an additional 35,196 shares during the period. Sanctuary Advisors LLC boosted its stake in shares of CRISPR Therapeutics by 17.8% during the third quarter. Sanctuary Advisors LLC now owns 8,317 shares of the company's stock valued at $398,000 after purchasing an additional 1,258 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics in the third quarter worth about $40,000. Franklin Resources Inc. increased its stake in CRISPR Therapeutics by 12.7% in the 3rd quarter. Franklin Resources Inc. now owns 7,097 shares of the company's stock worth $339,000 after buying an additional 800 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in CRISPR Therapeutics by 4.4% during the 4th quarter. Nordea Investment Management AB now owns 125,400 shares of the company's stock valued at $4,913,000 after buying an additional 5,300 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Price Performance

NASDAQ CRSP traded down $0.01 during trading on Friday, hitting $37.77. The company's stock had a trading volume of 1,027,190 shares, compared to its average volume of 1,631,291. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The company has a market cap of $3.24 billion, a PE ratio of -8.64 and a beta of 1.85. The business's 50 day simple moving average is $40.93 and its 200-day simple moving average is $43.76.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Activity

In related news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. This represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 over the last ninety days. 4.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on CRSP shares. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price on the stock in a research report on Wednesday, February 12th. HC Wainwright restated a "buy" rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Morgan Stanley upped their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a report on Friday, February 14th. JMP Securities restated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Finally, Chardan Capital lowered their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $73.11.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.